Compare Stocks: SLS, KYMR, ARWR, and PTGX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARWR Arrowhead Pharmaceuticals	$65.46 -0.7%	$82.33	$33.02 ▼ $95.49	$9.29B	1.28	2.17 million shs	1.50 million shs
KYMR Kymera Therapeutics	$112.00 +0.0%	$114.71	$54.09 ▼ $130.05	$9.31B	1.96	717,351 shs	723,650 shs
PTGX Protagonist Therapeutics	$142.44 +0.4%	$144.86	$62.24 ▼ $160.81	$9.18B	1.8	642,977 shs	925,457 shs
SLS SELLAS Life Sciences Group	$11.59 -0.2%	$12.40	$1.39 ▼ $15.88	$2.34B	2.52	6.30 million shs	3.75 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARWR Arrowhead Pharmaceuticals	-0.70%	-4.84%	-22.91%	-19.69%	+99.57%
KYMR Kymera Therapeutics	+0.04%	-4.82%	-5.21%	-2.33%	+99.11%
PTGX Protagonist Therapeutics	+0.41%	-1.75%	-1.31%	+16.20%	+111.27%
SLS SELLAS Life Sciences Group	-0.17%	+1.93%	-12.26%	-21.48%	+611.04%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARWR Arrowhead Pharmaceuticals	$65.46 -0.7%	$82.33	$33.02 ▼ $95.49	$9.29B	1.28	2.17 million shs	1.50 million shs
KYMR Kymera Therapeutics	$112.00 +0.0%	$114.71	$54.09 ▼ $130.05	$9.31B	1.96	717,351 shs	723,650 shs
PTGX Protagonist Therapeutics	$142.44 +0.4%	$144.86	$62.24 ▼ $160.81	$9.18B	1.8	642,977 shs	925,457 shs
SLS SELLAS Life Sciences Group	$11.59 -0.2%	$12.40	$1.39 ▼ $15.88	$2.34B	2.52	6.30 million shs	3.75 million shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARWR Arrowhead Pharmaceuticals	-0.70%	-4.84%	-22.91%	-19.69%	+99.57%
KYMR Kymera Therapeutics	+0.04%	-4.82%	-5.21%	-2.33%	+99.11%
PTGX Protagonist Therapeutics	+0.41%	-1.75%	-1.31%	+16.20%	+111.27%
SLS SELLAS Life Sciences Group	-0.17%	+1.93%	-12.26%	-21.48%	+611.04%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARWR Arrowhead Pharmaceuticals	2.64	Moderate Buy	$98.31	50.18% Upside
KYMR Kymera Therapeutics	2.88	Moderate Buy	$133.21	18.94% Upside
PTGX Protagonist Therapeutics	2.89	Moderate Buy	$147.13	3.29% Upside
SLS SELLAS Life Sciences Group	2.33	Hold	$10.00	-13.72% Downside

Current Analyst Ratings Breakdown

Latest SLS, KYMR, ARWR, and PTGX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/24/2026	ARWR Arrowhead Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Neutral	$74.00
9/23/2026	KYMR Kymera Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$140.00
9/22/2026	KYMR Kymera Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$132.00 ➝ $152.00
9/14/2026	KYMR Kymera Therapeutics	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$123.00 ➝ $144.00
9/10/2026	KYMR Kymera Therapeutics	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Peer Perform ➝ Outperform	$180.00
9/8/2026	ARWR Arrowhead Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$108.00
9/1/2026	PTGX Protagonist Therapeutics	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$153.00 ➝ $180.00
9/1/2026	ARWR Arrowhead Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$120.00
9/1/2026	PTGX Protagonist Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$178.00 ➝ $190.00
8/31/2026	PTGX Protagonist Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$175.00 ➝ $182.00
8/31/2026	PTGX Protagonist Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform

(Data available from 9/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARWR Arrowhead Pharmaceuticals	$829.45M	11.12	$0.12 per share	552.09	$3.64 per share	17.98
KYMR Kymera Therapeutics	$39.21M	237.51	N/A	N/A	$19.42 per share	5.77
PTGX Protagonist Therapeutics	$46.02M	200.29	N/A	N/A	$9.83 per share	14.49
SLS SELLAS Life Sciences Group	N/A	N/A	N/A	N/A	$0.46 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARWR Arrowhead Pharmaceuticals	-$1.63M	-$2.25	N/A	N/A	N/A	-47.79%	-60.06%	-17.37%	11/24/2026 (Estimated)
KYMR Kymera Therapeutics	-$311.35M	-$3.24	N/A	N/A	N/A	-285.33%	-21.22%	-19.21%	11/3/2026 (Estimated)
PTGX Protagonist Therapeutics	-$130.15M	$1.03	138.29	N/A	N/A	29.40%	12.03%	11.23%	11/5/2026 (Estimated)
SLS SELLAS Life Sciences Group	-$26.86M	-$0.21	N/A	N/A	N/A	N/A	-35.91%	-33.34%	11/11/2026 (Estimated)

Latest SLS, KYMR, ARWR, and PTGX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	SLS SELLAS Life Sciences Group	-$0.0450	-$0.05	-$0.0050	-$0.05	N/A	N/A
8/5/2026	Q2 2026	KYMR Kymera Therapeutics	-$0.7126	-$0.62	+$0.0926	-$0.62	$32.78 million	$65.00 million
8/5/2026	Q2 2026	PTGX Protagonist Therapeutics	$2.27	$2.29	+$0.02	$2.29	$212.03 million	$213.48 million
8/4/2026	Q3 2026	ARWR Arrowhead Pharmaceuticals	-$1.23	-$1.36	-$0.13	-$1.36	$44.17 million	$75.25 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARWR Arrowhead Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
KYMR Kymera Therapeutics	N/A	N/A	N/A	N/A	N/A
PTGX Protagonist Therapeutics	N/A	N/A	N/A	N/A	N/A
SLS SELLAS Life Sciences Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARWR Arrowhead Pharmaceuticals	1.77	5.90	5.90
KYMR Kymera Therapeutics	N/A	10.34	10.34
PTGX Protagonist Therapeutics	N/A	21.71	21.71
SLS SELLAS Life Sciences Group	N/A	18.83	18.83

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARWR Arrowhead Pharmaceuticals	62.61%
KYMR Kymera Therapeutics	N/A
PTGX Protagonist Therapeutics	98.63%
SLS SELLAS Life Sciences Group	17.38%

Insider Ownership

Company	Insider Ownership
ARWR Arrowhead Pharmaceuticals	3.60%
KYMR Kymera Therapeutics	15.98%
PTGX Protagonist Therapeutics	5.19%
SLS SELLAS Life Sciences Group	1.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARWR Arrowhead Pharmaceuticals	711	140.86 million	135.79 million	Optionable
KYMR Kymera Therapeutics	273	83.15 million	69.86 million	Optionable
PTGX Protagonist Therapeutics	141	64.71 million	61.35 million	Optionable
SLS SELLAS Life Sciences Group	13	201.95 million	199.32 million	Not Optionable

SLS, KYMR, ARWR, and PTGX Headlines

Recent News About These Companies

SELLAS Life Sciences präsentiert auf der AACR-Konferenz 2026 zu Bauchspeicheldrüsenkrebs präklinische Daten zur Wirksamkeit von SLS009 in Pankreaskrebsmodellen

September 26 at 1:39 AM | de.marketscreener.comD

SELLAS Life Sciences Presents Preclinical Data Demonstrating SLS009 Activity in Pancreatic Cancer Models at the 2026 AACR Conference on Pancreatic Cancer

September 25, 2026 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS

September 24, 2026 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS

September 22, 2026 | globenewswire.com

SELLAS Life Sciences: Valued For Perfection, REGAL Trial Success Probability Priced In

September 21, 2026 | seekingalpha.com

SELLAS Life Sciences Group (NASDAQ:SLS) Shares Gap Down - Should You Sell?

September 17, 2026 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS

September 17, 2026 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS

September 15, 2026 | globenewswire.com

SELLAS Life Sciences Group (NASDAQ:SLS) Shares Down 4.8% - Here's Why

September 11, 2026 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS

September 10, 2026 | prnewswire.com

Wellington Management Group LLP Grows Stock Holdings in SELLAS Life Sciences Group, Inc. $SLS

September 9, 2026 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS

September 8, 2026 | globenewswire.com

SELLAS Life Sciences Group, Inc. (SLS)

September 4, 2026 | finance.yahoo.com

Bank of New York Mellon Corp Makes New Investment in SELLAS Life Sciences Group, Inc. $SLS

September 4, 2026 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS

September 3, 2026 | prnewswire.com

SELLAS Life Sciences Group (SLS) Lands 3 AACR Abstracts For SLS009 Pancreatic Cancer Data

September 3, 2026 | finance.yahoo.com

Most and least shorted mid- to mega-cap healthcare stocks at the end of August

September 2, 2026 | seekingalpha.com

Sellas gears up to present preclinical SLS009 data for pancreatic cancer at major oncology conference

September 2, 2026 | msn.com

SELLAS Life Sciences to Present Preclinical Data on SLS009 in Pancreatic Ductal Adenocarcinoma at the 2026 AACR Conference on Pancreatic Cancer

September 2, 2026 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS

September 1, 2026 | globenewswire.com

Why analysts think Sellas Life Sciences stock can gain 150% from here

September 1, 2026 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

SLS, KYMR, ARWR, and PTGX Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

$65.46 -0.46 (-0.70%)

Closing price 09/28/2026 04:00 PM Eastern

Extended Trading

$65.74 +0.28 (+0.42%)

As of 08:19 AM Eastern

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Kymera Therapeutics NASDAQ:KYMR

$112.00 +0.05 (+0.04%)

Closing price 09/28/2026 04:00 PM Eastern

Extended Trading

$112.74 +0.74 (+0.66%)

As of 08:03 AM Eastern

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Protagonist Therapeutics NASDAQ:PTGX

$142.44 +0.58 (+0.41%)

Closing price 09/28/2026 04:00 PM Eastern

Extended Trading

$142.44 0.00 (0.00%)

As of 07:52 AM Eastern

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

SELLAS Life Sciences Group NASDAQ:SLS

$11.59 -0.02 (-0.17%)

Closing price 09/28/2026 04:00 PM Eastern

Extended Trading

$11.60 +0.02 (+0.13%)

As of 08:19 AM Eastern

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SLS, KYMR, ARWR, and PTGX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SLS, KYMR, ARWR, and PTGX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SLS, KYMR, ARWR, and PTGX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

SLS, KYMR, ARWR, and PTGX Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

Kymera Therapeutics NASDAQ:KYMR

Protagonist Therapeutics NASDAQ:PTGX

SELLAS Life Sciences Group NASDAQ:SLS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SLS, KYMR, ARWR, and PTGX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SLS, KYMR, ARWR, and PTGX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SLS, KYMR, ARWR, and PTGX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

SLS, KYMR, ARWR, and PTGX Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

Kymera Therapeutics NASDAQ:KYMR

Protagonist Therapeutics NASDAQ:PTGX

SELLAS Life Sciences Group NASDAQ:SLS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools